CSPC Group (01093): SYS 6040 (antibody-conjugated drug) was approved for clinical trials in the US

Zhitongcaijing · 06/10 09:57

Zhitong Finance App News, Shiyao Group (01093) issued an announcement. The new drug clinical trial (IND) application for SYS 6040 (antibody-conjugated drug) developed by the group has been approved by the US Food and Drug Administration (FDA), and clinical research can be carried out in the US. The product was also approved by the China National Drug Administration to conduct clinical trials in China in March 2025.

This product is a monoclonal antibody conjugate drug that binds to specific receptors on the surface of tumors to enter cells and release toxins through endocytosis to achieve the effect of killing tumor cells. The clinical indication approved this time is advanced solid tumors. Preclinical studies have shown that this product has good anti-tumor effects on various types of cancer and has high clinical development value. At present, the Group has submitted multiple patent applications for this product at home and abroad.